TRUSTwdl[®]



Store at 2-8 °C upon receipt

INTENDED USE

The Dengue IgG ELISA is a solid-phase enzyme-linked immunosorbent assay for the qualitative detection of elevated anti-dengue viruses (DEN1, 2, 3, 4) IgG in human serum or plasma. It is intended for professional use only as an aid in the diagnosis of active infection with dengue viruses, including secondary infection.

INTRODUCTION

Dengue virus is an enveloped, single-stranded, positive-sense RNA virus that belongs to the Flaviviridae family and can be classified into four distinct serotypes (DEN1, 2, 3, 4). The virus is transmitted by daytime-biting mosquitoes, principally Aedes aegypti and Aedes albopictus. Currently, more than 2.5 billion people living in tropical and subtropical areas of Asia, Africa, Australia, and the Americas are at risk for dengue infection. An estimated 67-136 million cases of dengue fever and 20,000 deaths occur annually on a worldwide basis¹⁻³.

Serological detection is a common method for the diagnosis of infection with dengue virus. During a primary infection, IgM anti-dengue virus starts to appear approximately 4-6 days after the onset of fever, peaks after approximately two weeks, and remains in circulation for about 2-3 months^{4,6}. IgG anti-dengue virus levels, increase slowly, peak around 14-21 days, and then decrease to low levels, persisting for life⁶.

During secondary infection, a strong and rapid IgG antibody response is often observed. IgG levels are detectable as early as 3 days after the onset of symptoms, with the peak detection window being 1-2 weeks after symptom onset. In secondary infection, IgG antibodies rise to levels higher than during the primary infection⁷ Importantly, anti-dengue IgG antibodies increase earlier than or simultaneously with IgM antibodies, and at much higher levels during secondary infection4-6

The Dengue IgG ELISA uses recombinant dengue virus antigens to specifically detect IgG antibodies against all four dengue virus serotypes (DEN1, 2, 3 and 4).

TEST PRINCIPLE

The Dengue IgG ELISA Kit is a solid-phase enzyme-linked immunosorbent assay based on the principle of the capture immunoassay methodology for the detection of loG anti-denoue virus in human serum or plasma.

The Dengue IgG ELISA Kit is composed of two key components:

- 1) Solid microwells pre-coated with mouse monoclonal anti-human IgG antibody.
- 2) Conjugate composed of biotinylated dengue antigens and avidin HRP-conjugates.

During the assay, the test specimen is first incubated in the coated microwell. IgG antidengue, if present in the specimen, binds to the anti-human log antibodies coated on the microwell surface, and any unbound specimen is then removed by a wash step. During a second incubation with Biotinylated dengue antigens, the IgG anti-dengue absorbed on the surface of microwell binds with dengue antigen, forming a complex. Unbound antigens are then removed by washing. After addition of Streptavidin HRP conjugate, it binds with biotinylated antigen and forming complex with HRP conjugate. After addition of the TMB substrate, the presence of the conjugate complex is shown by development of a blue color resulting from a reaction between the enzyme and substrate. This reaction is then quenched by addition of the Stop Solution, and the absorbance value for each microwell is determined using a spectrophotometer at 450/620-690 nm.

MATERIALS AND REAGENTS

Materials and reagents provided with the kit

	• •		
Item 1	Description Anti-human IgG Coated Microwells	Quantity 8 wells x 12 strips	Catalog AE0311W
2	Biotinylated Ag mix (251X concentrate)	100 µL	AE0311Ag
3	HRP conjugates	12 mL	AE0311H
4	Dengue IgG Positive Control	100 µL	AE0311P
5	Dengue IgG Negative Control	100 µL	AE0311N
6	Sample Diluent	90 mL	AE0311SD
7	Wash Buffer (30X Concentrate)	30 mL	AWE3000
8	TMB Substrate A	6 mL	ATME2000A
9	TMB Substrate B	6 mL	ATME2000B
10	Stop Solution	12 mL	ASE1000
11 12	ELISA Working Sheet Product Insert	2 1	AE0001ES PI-AE0311

Materials and reagents required but not provided in the kit

- Pipette capable of delivering 5 µL, 50 µL and 100 µL volumes with a precision better than 98.5%
- Microplate reader with a bandwidth of 10 nm or less and an optical density 2 range of 0-3 OD or greater at 450 nm wavelength is acceptable
- 3. Absorbent paper for blotting the microwells
- 4. Timer 5.
 - Distilled or de-ionized water

STORAGE AND STABILITY

All reagents except Dengue Antigen Mix and concentrated Wash Buffer are ready to use as supplied. Store all components at 2-8°C. Do not freeze. Ensure that the reagents are brought to room temperature before opening. Return all reagents requiring storage at 2-8°C to refrigeration immediately after use. Re-seal the unused microwells in provided Ziploc bag with desiccant. All reagents are stable through the expiration date printed on the label if not opened. Once opened, the kit is stable for 8 weeks at 2-8°C, or until the labeled expiration date, whichever is earlier.

SPECIMEN COLLECTION AND PREPARATION

- 1. Serum or plasma should be prepared from a whole blood specimen obtained by acceptable venipuncture technique.
- 2. This Test is designed for use with serum or plasma specimens without additives only
- If a specimen is not tested immediately, refrigerate at 2-8°C for up to 3 days. 3. For storage longer than 3 days, the specimen should be frozen at -20°C. Avoid multiple freeze-thaw cycles. If a specimen is to be shipped, pack in compliance with federal regulations covering the transportation of etiologic agents.
- Specimens containing precipitates may give inconsistent test results. Clarify 4. such specimens by centrifugation prior to performing the assay.
- 5. Do not use specimens demonstrating gross lipemia, gross hemolysis or turbidity. Do not use specimens containing sodium azide

PREPARATION OF THE REAGENTS PRIOR TO ASSAYING

- Bring all reagents and controls to room temperature (20-25°C). 1.
- Determine the volumes of antigen working solution and wash buffer required 2. for the assay. Each strip of microwells requires 900 µL of antigen working solution and 60 mL of working wash buffer. 3.
 - Preparation of antigen working solution (1X): Dilute the Biotinylated antigen mix 250 fold with Sample Diluent: e.g. to 10 µL of concentrated Biotinylated Ag mix (251X), add 2.5 mL Sample Diluent. antigen working solution(1X) is stable at 2-8 °C for 7 days.

Preparation of dengue IgG controls and specimens: 4.

Dilute the Dengue IgG Negative Control, Positive Control and patient specimens 100 fold with Sample Diluent: e.g. to 5 µL of control or specimen, add 500 uL Sample Diluent.

5. Preparation of working Wash Buffer:

If precipitants are visible, warm the Wash Buffer to 37°C. Dilute concentrated Wash Buffer 30 fold with distilled or de-ionized water as follows:

Plate	DI water	Wash buffer (30X)	Final volume
1 strip	58 mL	2 mL	60 mL
2 strips	116 mL	4 mL	120 mL
3 strips	174 mL	6 mL	180 mL
6 strips	348 mL	12 mL	360 mL

- 6. Mix each reagent before adding it to the test wells.
- Determine the number of microwells needed and mark the ELISA working 7. sheet with the appropriate information. Run positive and negative controls in duplicate to ensure accuracy.

ASSAY PROCEDURE

- 1. Remove the desired number of strips and secure them in the microwell frame. Reseal un-used strips in Ziploc bag.
- 2. Add specimens according to the designation on the ELISA Working Sheet: 2.1 Blank well: Do not add specimens or control.
- 2.2 Control wells: Add 100 µL diluted Dengue IgG Positive Control and 100 µL
- diluted Dengue IgG Negative Control into the designated control wells. 2.3 Test wells: Add 100 µL diluted patient specimen into each designated test well.
- 2.4 Gently rock the plate for 20 seconds, and then cover the plate with the sealer.
- Incubate the plate at 37°C for 30 minutes. Wash to remove unbounded materials: 3. 4

Manual washing: Carefully remove the incubation mixture by disposing of solution into a waste container. Fill each well with 350 µL diluted wash buffer and rock gently for 20-30 seconds. Discard the wash solution completely. Repeat 4 more times. After completing the last wash step, tap the plate on absorbent paper to remove residual liquid. Automated washing: Automatic plate washer must be calibrated to ensure

efficient washing. Fill each well with 350 μ L diluted wash buffer and soak for 20-30 seconds. Aspirate all wells completely. Repeat 4 more times.

- 5 Add 100 µL prepared antigen working solution(1X) into each well except the blank well. Gently rock the microwells for 20 seconds to ensure thorough mixing.
- Cover the wells and incubate at 37 °C for 45 minutes. 6.
- 7. Wash the plate 5 times as described in step 4.

- Add 100 µL of HRP conjugate into each well except the blank well. 8.
- 9 Cover the wells and incubate at 37°C for 20 minutes
- 10. Wash the plate 5 times as described in step 4.
- Add 50 μL TMB Substrate A and 50 μL TMB Substrate B into each well. 11. including the Blank Well. Gently rock the microwells for 20 seconds to ensure thorough mixing.
- Incubate at room temperature (20-25°C) in the dark for 15 minutes. 12.
- Stop the reaction by adding 100 µL Stop Solution to each well, including the 13. Blank Well. Gently rock for 20 seconds. Pipette the Stop Solution in the same sequence as substrate addition. It is important to make sure that all the blue color completely changes to the color yellow.
- 14. Set the microplate reader wavelength at 450 nm. Measure the absorbance (OD) of each well against the blank well within 30 minutes after adding Stop Solution. A filter of 620-690 nm can be used as a reference wavelength to optimize the assay result.

Flow shart of access procedure

FIOW	chart of assay procedure	
1.	Secure strips in microwell frame	Number of strips
2.	Add diluted controls or specimens. Gently rock	100 µL 20 seconds
3.	Incubate	37°C, 30 minutes
4.	Wash: manual or automatic	5 times
5.	Add antigen working solution. Gently rock	100 μL 20 seconds
6.	Incubate	37°C, 45 minutes
7.	Wash: manual or automatic	5 times
8.	Add HRP conjugate	100 µL
9.	Incubate	37°C, 20 minutes
10.	Wash: manual or automatic	5 times
11.	Add TMB Substrate A and TMB Substrate B	50 μL + 50 μL 20 seconds
12.	Incubate in dark	RT (20-25°C) 15 minutes
13.	Add Stop Solution. Gently rock	100 μL, 20 seconds
14.	Read result	450/620-690 nm within 30 minutes

INTERPRETATION OF RESULTS

Set up the cut-off value A.

The cut-off value = 0.25 + NC NC: Mean OD of the Negative Control.

В. Calculation of specimen OD ratio

Calculate an OD ratio for each specimen by dividing its OD value by the cut-off value as follows:

```
Specimen OD
Specimen OD ratio =
```

Cut-off Value

C. Assay Validation

The mean OD value of the positive controls should be > 0.50 The mean OD value of the negative controls should be ≤ 0.13 If above specification are not met, the assay is Invalid. Check the assay procedure including incubation time and temperature and repeat assay

D. Interpretation of the results

	Specimen OD ratio		
Negative	< 1.0		
Positive	> 1.0		

A negative result indicates that there is no detectable IgG anti-dengue antibody 1. in the specimen

- Results just below the cut-off value (lower than 10% of the cut-off value) should be interpreted with caution (it is advisable to re-test in duplicate the corresponding specimens when it is applicable).
- Specimens with OD ratio ≥ 1.0 are initially considered to be positive by the Dengue IgG ELISA Kit. They should be retested in duplicate before a final interpretation is made.

If after re-testing of a specimen, the absorbance value of the 2 duplicates are less than the cut-off value, the initial result is non-repeatable and the specimen is considered to be negative with the Dengue IgG ELISA Kit.

Non-repeatable reactions are often caused by:

- Inadequate microwell washing,
- Contamination of negative specimens by serum or plasma with a high antibody titer,
- Contamination of the substrate solution by oxidizing agents (bleach, metal ions, etc.),
- Contamination of the Stop Solution.

If after retesting the absorbance of one of the duplicates is equal to or greater than the cut-off value, the initial result is repeatable and the specimen is considered to be positive with the Dengue IgG ELISA Kit, subject to the limitations of the procedure, described below.

PERFORMANCE CHARACTERISTICS

1. Accuracy of Detection

A total of 262 patient specimens were collected from susceptible subjects and tested by Dengue IgG ELISA Kit and by a commercial leading brand EIA. Comparison for all subjects is shown in the following table:

	Dengue IgG ELISA		
Reference EIA	Positive	Negative	Total
Positive	40	2	42
Negative	7	213	220
Total	47	215	262

Relative Sensitivity: 95.2% (95% Confidence Interval = 83.8 – 99.4%) Relative Specificity: 96.8% (95% Confidence Interval = 93.6 – 98.7%) Overall agreement: 96.6% (95% Confidence Interval = 93.6 – 98.4%)

2. Cross-Reactivity

No false positive Dengue IgG ELISA test results were observed on 2-10 positive specimens from each of the following disease states or special conditions, respectively: CHIK HCV HBsAg HIV Malaria Syphilis Typhoid

3. Interference

Common substances (such as pain and fever medication and blood components) may affect the performance of the Dengue IgG ELISA Kit. Interference was studied by spiking these substances into 3 dengue IgG clinical specimens: negative, low positive and high positive. The results demonstrate that at the concentrations tested, the substances studied do not affect the performance of the Dengue IgG ELISA Kit.

List of potentially interfering substances and concentrations tested:				
 Salicylic acid 	4.34 mmol/L	5. Glucose	55 mmol/L	
2. Sodium citrate	1.3 %	6. Heparin	3,000 U/L	
Creatinine	442 µmol/L	7. Bilirubin	10 mg/dL	
4. EDTA	3.4 µmol/L		-	

WARNING AND PRECAUTIONS

For In Vitro Diagnostic Use

- 1. This package insert must be read completely before performing the test. Failure to follow the insert may lead to inaccurate test results.
- 2. Bring all reagents to room temperature (20-25°C) before use.
- 3. Do not use expired test kits.
- Do not use the components from any other type of test kit as a substitute for the components in this kit.
- 5. Do not use hemolyzed blood specimens for testing.
- Do not ingest the reagents. Avoid contact with eyes, skin and mouth. Wear protective clothing and disposable gloves while handling the kit reagents and clinical specimens. Wash hands thoroughly after performing the test.
- Do not smoke, drink or eat in areas where specimens or kit reagents are being handled.
- The human serum materials used for the preparation of controls have been tested and found non-reactive with antibodies to HIV-1 & 2, HCV, and HBSAQ. However, users of this test should follow the US CDC Universal Precautions for prevention of transmission of HIV, HBV and other blood-borne pathogens.
- Dispose of all specimens and materials used to perform the test as biohazardous waste.
- At the beginning of each incubation, and after the addition of Stop Solution, gently rock the microwells for 20 seconds to ensure thorough mixing and even

distribution. Avoid the formation of air bubbles which results in inaccurate absorbance values. Avoid splashing liquid while rocking or shaking the wells. Do not allow the microwells to dry between the end of the washing operation

- 11. Do not allow the microwells to dry between the end of the washing operatio and the reagent distribution.
- The enzyme-substrate reaction is very sensitive to metal ions. Do not allow any metal element to come into contact with the conjugate or substrate solution.
- The enzyme-substrate is temperature dependent. Ensure that the room temperature for TMB incubation falls between 20-25°C.
- The TMB Substrate must be colorless. The appearance of color indicates that the reagent cannot be used and must be replaced. The TMB Substrate B must be stored in the dark.
- Use a new distribution tip for each specimen and working step. Never use the specimen container to distribute dispense conjugate and TMB Substrate.
- 16. The wash procedure is critical. Wells must be aspirated completely before adding the wash buffer or liquid reagents. Automatic washer must be validated with Dengue IgG ELISA Kit prior to use. Insufficient washing will result in poor precision and falsely elevated absorbance values.
- Microplate reader must be calibrated per manufacturer's instruction to ensure accurate determination of absorbance. Non-calibrated readers often lead to invalid test results.
- 18. Avoid exposure of the wells to strong light during color development.

LIMITATION OF THE TEST

- The Assay Procedure and the Interpretation of Results must be followed closely when testing for the presence of antibodies to dengue virus in serum or plasma from individual subjects. Failure to follow the procedure may give inaccurate results.
- The Dengue IgG ELISA Kit limited to the detection of high titer IgG antibodies associated with secondary dengue infection. However, it has been proposed that antibody ratios (IgG/IgM) can be used to distinguish between primary and secondary dengue infections⁵.
- Serological cross reactivity with other flaviviruses is common (e.g., Japanese encephalitis, West Nile, yellow fever, etc.), therefore, it is possible that patients infected with these viruses may show some level of the reactivity with this test.
- A negative result for an individual subject indicates absence of detectable dengue virus antibodies. However, a negative test result does not preclude the possibility of exposure to or infection with dengue virus.
- A negative result can occur if the titer of the dengue IgG antibodies present in the specimen is below the detection limit of the assay, or the IgG antibodies that are detected are not present during the stage of disease in which a specimen is collected.
- Infection may progress rapidly. If the symptoms persist, while the result from the Dengue IgG ELISA Kit is negative, it is recommended to test with an alternative test method.
- Some specimens containing unusually high titers of heterophile antibodies or rheumatoid factor may affect the expected results.
- 8. Any interpretation or use of this test result must also rely on other clinical findings as well as on the professional judgment of health care providers.

REFERENCES

- Anonymous Dengue: prevention and control. EXECUTIVE BOARD, 136th session, Report by the Secretariat. Geneva: World Health Organization, 21 November 2014.
- Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature 2013; 496:504–507.
- Anonymous Global strategy for dengue prevention and control. Geneva: World Health Organization, 2012.
- Tang KF. Ooi EE. Diagnosis of dengue: an update. Expert Rev Anti Infect Ther 10 (8), 895-907 (2012).
- Halstead SB, Suaya JA, Shepard DS. The burden of dengue infection. Lancet, 2007; 369:1410-1411.
- Peeling RW et al. Evaluation of diagnostic tests: dengue. Nature Reviews Microbiology 8, S30-S37. 2010.

Index of symbols



